GIP and obesity disorder: Numerous clinical studies have evaluated the effects of GLP-1RAs, as well as the dual GIP/GLP-1 RA tirzepatide, on gastric emptying as a primary or secondary endpoint in subjects with T2D and those with obesity but without diabetes (69).